|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in immunotherapy for treatment of lung cancer显示文摘Different approaches for treating lung cancer have been developed over time, including chemotherapy, radiotherapy and targeted therapies against activating mutations. Lately, better understanding of the role of the immunological system in tumor control has opened multiple doors to implement different strategies to enhance immune response against cancer cells. It is known that tumor cells elude immune response by several mechanisms. The development of monoclonal antibodies against the checkpoint inhibitor programmed cell death protein 1(PD-1) and its ligand(PD-L1), on T cells, has led to high activity in cancer patients with long lasting responses. Nivolumab, an anti PD-1 inhibitor, has been recently approved for the treatment of squamous cell lung cancer patients, given the survival advantage demonstrated in a phase III trial. Pembrolizumab, another anti PD-1 antibody, has received FDA breakthrough therapy designation for treatment of non-small cell lung cancer(NSCLC), supported by data from a phase I trial. Clinical trials with anti PD-1/PD-L1 antibodies in NSCLC have demonstrated very good tolerability and activity, with response rates around 20% and a median duration of response of 18 months. | Jean G.Bustamante Alvarez María González-Cao Niki Karachaliou Mariacarmela Santarpia Santiago Viteri Cristina Teixidó Rafael Rosell | 2015 | Cancer Biology & Medicine2015，12，3： | 22 |
| 2 | Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population显示文摘● AIM: To assess if the included vascular endothelial growth factor(VEGF) polymorphisms rs3025035, rs3025021 and rs2010963 are associated to proliferative retinopathy in a Mexican population with type 2 diabetes mellitus(T2DM).● METHODS: A case-control study was conducted in adult individuals with T2 DM associated to proliferative retinopathy or non-proliferative retinopathy from Oct. 2014 to Jun. 2015 from the Retina Department of the Asociation to Prevent Blindness in Mexico. The selected patients were adults with a diagnosis of T2 DM ≥5y. All subjects had a comprehensive ocular examination and the classification of the retinopathy severity was made considering the Early Treatment Diabetic Retinopathy Study(ETDRS) standardization protocols. Genomic DNA was extracted from whole fresh blood. All samples were genotyped by q PCR for selected VEGF polymorphisms. Hardy-Weinberg equilibrium was calculated by comparing Chi-square values between the expected and the observed values for genotype counts.● RESULTS: In total 142 individuals were enrolled, 71 individuals with T2 DM and associated proliferative retinopathy and 71 individuals with non-proliferative retinopathy. One-sided Fisher's exact test was performed for rs3025021[OR(95% CI)=0.44(0.08-2.2); P=0.25] and rs2010963 [OR(95% CI)=0.63(0.25-1.6); P=0.23]. The minor allelic frequencies obtained were 26% for rs3025021, 10% for rs3025035 and 61% for rs2010963. The pairwise linkage disequilibrium between the three SNP was assessed, and was as follows: rs3025021 vs rs3025035: D'=1.0, r^2=0.1043, P≤0.0001; rs3025021 vs rs2010963: D'=0.442, r^2=0.0446, P=0.149; rs3025035 vs rs2010963: D'=0.505, r^2=0.0214, P=0.142.● CONCLUSION: This is the first analysis involving VEGFA polymorphisms and proliferative diabetic retinopathy in a Mexican population. A major finding of the present study is that none of the polymorphisms studied was significantly associated with proliferative retinopathy. Based on these results, we can infer that different populations have different associations for the same polymorphisms. | Roberto Gonzalez-Salinas Maria C Garcia-Gutierrez Gerardo Garcia-Aguirre Virgilio Morales-Canton Raul Velez-Montoya Vidal R Soberon-Ventura Victoria Gonzalez Rodrigo Lechuga Pablo Garcia-Solis David G Garcia-Gutierrez Marco Vinicio Garcia-Solis Manuel Saenz de Viteri Juan C Solis-S | 2017 | International Journal of Ophthalmology(English edition)2017，10，1： | 12 |
| 3 | Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints显示文摘Survival rates for metastatic lung cancer, including non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC), are poor with 5-year survivals of less than 5%. The immune system has an intricate and complex relationship with tumorigenesis; a groundswell of research on the immune system is leading to greater understanding of how cancer progresses and presenting new ways to halt disease progress. Due to the extraordinary power of the immune system—with its capacity for memory, exquisite specificity and central and universal role in human biology—immunotherapy has the potential to achieve complete, long-lasting remissions and cures, with few side effects for any cancer patient, regardless of cancer type. As a result, a range of cancer therapies are under development that work by turning our own immune cells against tumors. However deeper understanding of the complexity of immunomodulation by tumors is key to the development of effective immunotherapies, especially in lung cancer. | Niki Karachaliou Maria Gonzalez Cao Cristina Teixidó Santiago Viteri Daniela Morales-Espinosa Mariacarmela Santarpia Rafael Rosell | 2015 | Cancer Biology & Medicine2015，12，2： | 10 |
| 4 | A New Concept in the Control of Iron Deficiency:Community-based Preventive Supplementation of At-Risk Groups by the Weekly Intake of Iron Supplements显示文摘Iron deficiency (ID), defined as an insufficient supply of iron to the cells of the body after iron reserves have been exhausted, is the most prevalent single nutritional deficiency, affecting over 2, 000 million people, mostly in the developing world. Infants, small children, adolescents and pregnant and fertile-age women are most vulnerable. Only about 50 % of people with ID develop iron deficiency anemia (IDA), since this is a late manifes tation of chronic ID. Based on the average daily iron requirement and on the rate of iron reutilization from red cell hemoglobin destruction, it can be estimated that after iron stores have been depleted, it takes about 4 months of ID erythropoiesis for adult women to have a drop in hemoglobin concentration [Hb] of 10 g/l, if the iron intake is only 70 % of requirement. IDA can be defined by a [Hb] below an appropriate cut-off point for age,sex, physiological condition and altitude above sea level, or by a [Hb] increment of morethan 10 g/l to the administration of adequate doses of iron. More than 85 % of the nutritional anemias are IDA alone, or of iron combined with folate or other nutrient deficiencies [WHO/UNICEF/UNU, 1997; Yip, 1994]. | FERNANDO E. VITERI(Deportment of Nutrilional Sciences and Toxicology, University ofCalifornia at Berkeley and United Nations Uliversity,Berkeley 94720, Chlifornia, USA) | 1998 | Biomedical and Environmental Sciences1998，11，1： | 5 |
| 5 | Developmental deficits in iron-deficient infants: effects of age and severity of iron lack 显示文摘 | Lozoff B Brittenham GM Viteri ICE | 1982 | J Pediatr1982，101，： | 1 |
| 6 | The effects of shortterm oral iron therapy on developmental deficits in iron-deficient anemic infants 显示文摘 | Lozoff B Brittenham GM Viteri FE | 1982 | J Pediatr1982，100，： | 1 |
| 7 | Serum concentrations of β - carotene, vitamins C and E, zinc and selenimn are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population显示文摘 | Galan P Viteri FE Bertrais S | 2005 | Eur J Clin Nutr2005，59，： | 1 |
| 8 | Biweekly administration of eisplatin/gemcitabine in advanced nonsmall cell lung cancer 显示文摘 | Lopez-Vivanco G Viteri A Barcelo R | 2005 | Am J Clin Oncol2005，28，5： | 1 |
| 9 | Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy显示文摘 | Sharief M Viteri C Ben-Menachem E | 1996 | Epilepsy Res1996，25，3： | 1 |
| 10 | Iron and oxidative stress in pregnancy 显示文摘 | Casanueva E Viteri FE | 2003 | J Nutr2003，133，5： | 1 |
| 11 | Iron and oxidative stress in pregnancy显示文摘 | Viteri FE | 2003 | Journal of Nutrition2003，133，： | 1 |
| 12 | Biweekly administration of cisplatin/gemcitabine in advanced nonsmall cell lung cancer显示文摘 | Lopez-Vivanco G Viteri A Barcelo R | 2005 | Am J Clin Oncol2005，28，5： | 1 |
| 13 | Epilepsy and sleep显示文摘 | Viteri C | 2007 | Spanish2007，30，1： | 1 |
| 14 | Fortification of suger with FeNaDETA improves iron status in semirural Guatemalan populations显示文摘 | Viteri FE Alvarez E Baters R | 1995 | Am J Clin Nutr1995，61，： | 1 |
| 15 | Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by i- rons status 显示文摘 | BOVELL-BENJAMIN A C VITERI F E ALLEN L H | 2000 | American J of Clinical Nutrition2000，71，6： | 1 |
| 16 | Effect of genetically modified, low phytic acid maize on absorption of iron from tortillas 显示文摘 | Mendoza C Viteri F Lonnerdal B | 1998 | Am J Clin Nutr1998，68，5： | 1 |
| 17 | Double,placebocontrolled study of topiramate in patients with refractory partial epilepsy显示文摘 | Sharid M Viteri C Ben-Menaehem E | 1996 | Epilepsy Res1996，25，： | 1 |
| 18 | Effects and safety of preventive oral ironor iron + folic acid supplementation for women during pregnancy显示文摘 | Pena-Rosas JP Viteri FE | 2009 | Cochrane Database Syst Rev2009，，00： | 1 |
| 19 | Double -blind placebo- controll study of topiamate in patients with refractory epilepsy partial epilepsy显示文摘 | SHARIEF M VITERI C BEN - MENACHEM E | 1996 | Epilepsy Res1996，25，5： | 1 |
| 20 | Effect of progerin on the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford progeria patients显示文摘 | Viteri G Chung YW Stadtman ER | 2010 | Mech Ageing Dev2010，131，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员